Correction to: Early sepsis markers in patients admitted to intensive care unit with moderate‑to‑severe diabetic ketoacidosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2110-5820
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Early sepsis markers in patients admitted to intensive care unit with moderate‑to‑severe diabetic ketoacidosis ; volume:10 ; number:1 ; day:2 ; month:6 ; year:2020 ; pages:1 ; date:12.2020
Annals of intensive care ; 10, Heft 1 (2.6.2020), 1, 12.2020
- Urheber
-
Blanchard, Florian
Charbit, Judith
Van der Meersch, Guillaume
Popoff, Benjamin
Picod, Adrien
Cohen, Regis
Chemouni, Frank
Gaudry, Stephane
Bihan, Helene
Cohen, Yves
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13613-020-00691-7
- URN
-
urn:nbn:de:101:1-2020080323470264312273
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blanchard, Florian
- Charbit, Judith
- Van der Meersch, Guillaume
- Popoff, Benjamin
- Picod, Adrien
- Cohen, Regis
- Chemouni, Frank
- Gaudry, Stephane
- Bihan, Helene
- Cohen, Yves
- SpringerLink (Online service)
Ähnliche Objekte (12)
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year